ArticleJCO precision oncology2017
Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation.
Article in JCO precision oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Guideline
- TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.JCO precision oncology · 2024Trial
- Characteristics of Germline and Somatic Mutations of DNA Repair Genes in Korean Men with Prostate Cancer.The world journal of men's health · 2026Article
- A Social Media Campaign and Web-Based Survey About Prostate Cancer Genetics: Mixed Methods Study.JMIR cancer · 2025Article
- Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry.JCO precision oncology · 2025Article
- Review
- Incorporating Structured and Unstructured Data Sources to Identify and Characterize Hereditary Cancer Testing Among Veterans With Metastatic Castration-Resistant Prostate Cancer.JCO clinical cancer informatics · 2025Article
- Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.The Journal of urology · 2024Article
- Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency.Urology case reports · 2024Article
- Article
- Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing.BMC public health · 2024Article
- 2023 Canadian Urological Association guideline: Genetic testing in prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer.World journal of urology · 2023Article
- Review
- DNA repair deficiency as circulating biomarker in prostate cancer.Frontiers in oncology · 2023Review
- Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study.BMC cancer · 2022Article
- Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families.Journal of community genetics · 2022Article
- Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.JCO precision oncology · 2022Article
- Germline pathogenic variants in unselected Korean men with prostate cancer.Investigative and clinical urology · 2022Article
- Implications of ACMG guidelines to identify high-risk acute lymphoblastic leukemia patients with hereditary cancer susceptibility syndromes (HCSS) in a highly consanguineous population.BMC pediatrics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
Abstract
purposeMultigene panels are commercially available for the evaluation of prostate cancer (PCA) predisposition, which necessitates tailored genetic counseling (GC) for men. Here we describe emerging results of Genetic Evaluation of Men, prospective multigene testing study in PCA to inform personalized genetic counseling, with emerging implications for referrals, cancer screening, and precision therapy. PATIENTS AND
methodsEligibility criteria for men affected by or at high risk for PCA encompass age, race, family history (FH), and PCA stage/grade. Detailed demographic, clinical, and FH data were obtained from participants and medical records. Multigene testing was conducted after GC. Mutation rates were summarized by eligibility criteria and compared across FH data. The 95% CI of mutation prevalence was constructed by using Poisson distribution.
resultsOf 200 men enrolled, 62.5% had PCA. Eleven (5.5%; 95% CI, 3.0% to 9.9%) had mutations; 63.6% of mutations were in DNA repair genes. FH of breast cancer was significantly associated with mutation status (
conclusionMultigene testing for PCA identifies mutations mostly in DNA repair genes, with implications for precision therapy. The study highlights the importance of comprehensive genetic evaluation for PCA beyond metastatic disease, including early-stage disease with strong FH. Detailed FH is important for referrals of men for genetic evaluation. The results inform precision GC and cancer screening for men and their male and female blood relatives.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.